Distinguished in Temporal Arteritis

Jurgen J. Rech

Erlangen, BY, DE 
Distinguished in Temporal Arteritis
Erlangen, BY, DE 
OverviewLocationsClinical Research

Overview

Jurgen Rech practices in Erlangen, Germany. Rech is rated as a Distinguished expert by MediFind in the treatment of Temporal Arteritis. Their top areas of expertise are Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis (RA), and Adult Still's Disease.

Their clinical research consists of co-authoring 170 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 9 articles in the study of Temporal Arteritis.

Locations

Erlangen, BY, Germany
Other Locations
Bayern, BY, Germany
Munich, BY, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Study Protocol for a Multi-Centre, Placebo-Controlled Phase II Study of Canakinumab for the Treatment of Adult-onset Still's Disease (AOSD) Including an Open-label Long Term Extension
Study Protocol for a Multi-Centre, Placebo-Controlled Phase II Study of Canakinumab for the Treatment of Adult-onset Still's Disease (AOSD) Including an Open-label Long Term Extension
Enrollment Status: Terminated
Publish Date: August 07, 2020
Intervention Type: Drug
Study Phase: Phase 2
Prediction of Response to Certolizumab Pegol Treatment by Functional MRI of the Brain. A Multi-center, Randomized Double-blind Controlled Study Prediction of Response to Certolizumab-Pegol in RA (PreCePRA)
Prediction of Response to Certolizumab Pegol Treatment by Functional MRI of the Brain. A Multi-center, Randomized Double-blind Controlled Study Prediction of Response to Certolizumab-Pegol in RA (PreCePRA)
Enrollment Status: Completed
Publish Date: March 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

170 Total Publications

BCMA T-Cell Engager Therapy in Patients with Refractory Autoimmune Disease.
BCMA T-Cell Engager Therapy in Patients with Refractory Autoimmune Disease.
Journal: The New England journal of medicine
Published: October 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Rech's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 23 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile